Horseradish peroxidase conjugated donkey anti goat igg sc 2020

Seliciclib (CYC202, R-roscovitine) was provided by Cyclacel, Ltd (10mM stock solution in dimethyl sulfoxide, DMSO). The seliciclib dosage used (10μM) is clinically achievable (34 (link)) and biological effects of seliciclib at 10μM were due to CDK2 inhibition rather than CDK7/9 blockade in lung cancer cells (19 (link)). Antibodies used were: α-tubulin (T6199, Sigma Aldrich, (1:1000 immunofluorescence and 1:10000 immunoblot), α-tubulin (YL1/2) (NB600-506, Novus Biologicals, 1:1500), γ-tubulin (T5326, Sigma Aldrich, 1:1000), CP110 (12780-1-AP, Proteintech, 1:750), HA.11 clone 16B12 monoclonal antibody (MMS-101P, Covance, 1:3000), cyclin F (C-20) (SC-952, Santa Cruz Biotechnology, 1:500), CEP76 (A302-326A, Bethyl Laboratories, 1:1000), USP33 (A300-925A, Bethyl Laboratories, 1:1000 in 5%BSA) and KRAS (ab55391, Abcam, 1:1000). Secondary antibodies used were: Texas red anti-mouse IgG (H+L) (TI-2000, Vector Laboratories.), Fluorescein anti-mouse IgG (H+L) (FI-2000, Vector Laboratories.), Alexa fluor 594 donkey anti-rat IgG (H+L) (A21209, Invitrogen), ECL anti-rabbit lgG (NA934V, GE Healthcare), ECL anti-mouse lgG (NA931V, GE Healthcare) and horseradish peroxidase–conjugated donkey anti-goat IgG (sc-2020, Santa Cruz Biotechnology.). Hoechst 33342 (62249, Thermo Scientific, 1:25000) stained DNA. Pro-Long Gold anti-fade reagent (P36934, Invitrogen) preserved immunofluorescence.